Proteins and Peptides

08 Oct 2020 Ocular Therapeutix™ Announces Topline Phase 1 Clinical Trial Results of OTX-CSI
08 Oct 2020 Pfizer Announces Positive Phase 3 Top-line Results for Once-Weekly Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency
04 Oct 2020 Apellis Announces New Analysis Demonstrating Targeted C3 Therapy Pegcetacoplan Slows Progression of Early Disease in Patients with Geographic Atrophy (GA)
02 Oct 2020 EMA accepts regulatory submission for avalglucosidase alfa, a potentially new standard of care enzyme replacement therapy for Pompe disease
02 Oct 2020 Codiak Initiates Patient Dosing in Phase 1/2 Clinical Trial of exoSTING™ for the Treatment of Solid Tumors
01 Oct 2020 Sobi and Selecta Biosciences announce topline data of SEL-212 from the phase 2 COMPARE study supporting the potential for important clinical improvement in patients with Chronic Refractory Gout
29 Sep 2020 Ocular Therapeutix™ Announces First Patients Dosed in Phase 2 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease
29 Sep 2020 Ascendis Pharma A/S Announces Preliminary Six-Month Data from Open-Label Extension of Phase 2 PaTH Forward Trial and Files IND Amendment to Initiate Phase 3 PaTHway Trial of TransCon™ PTH in Adult Hypoparathyroidism
25 Sep 2020 NeoMatrix Announces Positive Topline Phase 1 Data for NMT-cP12
25 Sep 2020 Molecular Partners Presents Preclinical Data Supporting Tumor Localization Mechanism of its CD40 Agonist MP0317 at World Bispecific Summit
23 Sep 2020 First patient randomised in the phase 3 DISSOLVE clinical programme of SEL-212 for Chronic Refractory Gout
22 Sep 2020 Switching to investigational once-weekly insulin icodec from other basal insulins demonstrated to be efficacious and well-tolerated for people with type 2 diabetes in phase 2 trial
22 Sep 2020 Micreos initiates clinical trial to evaluate world's first endolysin-drug as a therapy for Atopic Dermatitis
18 Sep 2020 Amytrx Therapeutics Emerges from Stealth to Develop Novel Therapies for Inflammatory Diseases with Lead Program AMTX-100 Currently in Clinical Development for Dermatologic Indications
18 Sep 2020 Synthekine Launches with $82 Million Series A Financing to Advance Pipeline of Engineered Cytokine Therapeutics Optimized for Cancer and Autoimmune Diseases
16 Sep 2020 Codiak Initiates Subject Dosing in a Phase 1 Clinical Trial of exoIL-12™ for the Treatment of Cancer
16 Sep 2020 Takeda to Divest TachoSil® to Corza Health for €350 Million
14 Sep 2020 89bio Announces Positive Topline Results from its Phase 1b/2a Trial of BIO89-100 in NASH
14 Sep 2020 Attralus Presents Preclinical and Clinical Data at 17th International Symposium on Amyloidosis
14 Sep 2020 Molecular Partners Completes GMP Manufacturing of Anti-COVID-19 DARPin® Candidate MP0420 for Clinical Use
12 Sep 2020 Keros Therapeutics Presents Results from Preclinical Studies Investigating KER-012 at the American Society for Bone and Mineral Research 2020 Annual Meeting
12 Sep 2020 Partner Therapeutics Announces Start of Phase 3 Portion of Clinical Study of Leukine® in Combination with Ipilumimab and Nivolumab in Front Line Treatment of Melanoma
11 Sep 2020 Bicycle Therapeutics Announces First Patient Dosed in Phase I/II Trial of Bicycle® Toxin Conjugate BT8009 in Patients with Advanced Solid Tumors
10 Sep 2020 Gemini Therapeutics Enrolls First Patient in Phase 2a Study of GEM103 for Dry Age-related Macular Degeneration
09 Sep 2020 Ascendis Pharma A/S Submits Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for TransCon™ hGH for Treatment of Pediatric Growth Hormone Deficiency

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up